Chimerix's brincidofovir grabs Ebola spotlight; Tekmira fades
This article was originally published in Scrip
Executive Summary
For weeks, Tekmira Pharmaceuticals has been the darling of Wall Street, with the firm's experimental medicine, TKM-Ebola, sharing the spotlight with privately held Mapp Biopharmaceutical's ZMapp as the shining lights of hope against Ebola, a disease that is ravaging West Africa.